Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010603 · ClinicalTrials.gov registry record
Late Onset Alzheimer's Disease
A clinical trial of Alzheimer Disease, sponsored by Columbia University.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 12
- Study locations
NCT05010603 is a study of Alzheimer Disease that is actively recruiting participants, run by Columbia University. The registered enrollment target is 10,000 participants, above the 2,718-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (268% higher). The trial reports 12 study locations across 11 states.
The verdict
NCT05010603, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Conditions Studied
Interventions
- GENETIC Blood Draw
- OTHER Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Study Locations (12)
Indiana
- Indiana University - Bloomington
- NCRAD at Indiana University - Indianapolis
District of Columbia
- University of Washington - Washington D.C.
Florida
- University of Miami - Miami
Illinois
- Rush University - Aurora
Minnesota
- Mayo Clinic - Rochester
Missouri
- Joanne Norton - St Louis
New York
- Columbia University Irving Medical Center - New York
North Carolina
- North Carolina State University - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2027-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05010603
The ClinicalTrials.gov registry entry for NCT05010603 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,718-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (268% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Blood Draw is the first listed.
NCT05010603 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Indiana, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT05010603 about?
NCT05010603 is a clinical study titled "Late Onset Alzheimer's Disease". The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to ...
What is the current status of trial NCT05010603?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2016-11-15. Estimated completion is 2027-04-30.
What conditions does trial NCT05010603 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05010603?
The interventions under investigation include: Blood Draw (GENETIC), Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test (OTHER).
Who is sponsoring clinical trial NCT05010603?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010603 being conducted?
This trial has 12 study locations across District of Columbia, Florida, Illinois, Indiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.